A welcomed new myocardial perfusion imaging agent for positron emission tomography

Circulation

Volumn 119, Issue 17, 2009, Pages 2299-2301

  Beller, George A ^a   Watson, Denny D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA N 13; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; OXYGEN 15; RUBIDIUM 82; TETROFOSMIN TC 99M; BMS 747158 02; BMS 747158-02; CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUORINE; PYRIDAZINE DERIVATIVE;

CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EDITORIAL; ELECTROCARDIOGRAPHY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HUMAN; IMAGE QUALITY; NONHUMAN; PHARMACOLOGIC STRESS TESTING; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASODILATATION; ANIMAL; HALF LIFE TIME; HEART SCINTISCANNING; METHODOLOGY; NOTE;

ANIMALS; CONTRAST MEDIA; FLUORINE RADIOISOTOPES; HALF-LIFE; HUMANS; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; PYRIDAZINES;

EID: 66349112032     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.854919     Document Type: Editorial

References (23)

1. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol. 2004;11:171-85.
2. Venkataraman R, Hage FG, Dorfman T, Heo J, Aqel RA, de Mattos AM, Iskandrian AE. Role of myocardial perfusion imaging in patients with end-stage renal disease undergoing coronary angiography. Am J Cardiol. 2008;102:1451-1456.
3. Navare SM, Mather JF, Shaw LJ, Fowler MS, Heller GV. Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: a meta-analysis. J Nucl Cardiol. 2004;11:551-561.
4. Beller GA, Bergmann SR. Myocardial perfusion imaging agents: SPECT and PET. J Nucl Cardiol. 2004;11:71-86.
5. Schuijf JD, Poldermans D, Shaw LJ, Jukema JW, Lamb HJ, de Roos A, Wijns W, van der Wall EE, Bax JJ. Diagnostic and prognostic value of non-invasive imaging in known or suspected coronary artery disease. Eur J Nucl Med Mol Imaging. 2006;33:93-104.
6. Yoshinaga K, Chow BJ, Williams K, Chen L, deKemp RA, Garrard L, Lok-Tin Szeto A, Aung M, Davies RA, Ruddy TD, Beanlands RS. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol. 2006;48:1029-1039.
7. Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol. 1997;80: 865-870.
8. Parkash R, deKemp RA, Ruddy TD, Kitsikis A, Hart R, Beauchesne L, Williams K, Davies RA, Labinaz M, Beanlands RS. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol. 2004;11:440-449.
9. Di Carli MF, Dorbala S, Meserve J, El Fakhri G, Sitek A, Moore SC. Clinical myocardial perfusion PET/CT. J Nucl Med. 2007;48:783-793. Review.
10. Glover DK, Gropler RJ. Journey to find the ideal PET flow tracer for clinical use: are we there yet? J Nucl Cardiol. 2007;14:765-768.
11. Glover DK, Ruiz M, Edwards NC, Cunningham M, Simanis JP, Smith WH, Watson DD, Beller GA. Comparison between 201T1 and 99mTc sestamibi uptake during adenosine-induced vasodilation as a function of coronary stenosis severity. Circulation. 1995;91:813-820.
12. Shanoudy H, Raggi P, Beller GA, Soliman A, Ammermann EG, Kastner RJ, Watson DD. Comparison of technetium-99m tetrofosmin and thallium-201 single-photon emission computed tomographic imaging for detection of myocardial perfusion defects in patients with coronary artery disease. J Am Coll Cardiol. 1998;31:331-337.
13. Lima RS, Watson DD, Goode AR, Siadaty MS, Ragosta M, Beller GA, Samady H. Incremental value of combined perfusion and function over perfusion alone by gated SPECT myocardial perfusion imaging for detection of severe three-vessel coronary artery disease. J Am Coll Cardiol. 2003;42:64-70.
14. Jain D, He ZX. Direct imaging of myocardial ischemia: a potential new paradigm in nuclear cardiovascular imaging. J Nucl Cardiol. 2008;15: 617-630.
15. Watson DD, Smith WH II. The role of quantitation in clinical nuclear cardiology: the University of Virginia approach. J Nucl Cardiol. 2007;14:466-482.
16. Smanio PE, Watson DD, Segalla DL, Vinson EL, Smith WH, Beller GA. Value of gating of technetium-99m sestamibi single-photon emission computed tomographic imaging. J Am Coll Cardiol. 1997;30:1687-1692.
17. Goldstein RA, Mullani NA, Marani SK, Fisher DJ, Gould KL, O'Brien HA Jr. Myocardial perfusion with rubidium-82. II. Effects of metabolic and pharmacologic interventions. J Nucl Med. 1983;24:907-915.
18. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830-840.
19. Sampson UK, Dorbala S, Limaye A, Kwong R, Di Carli MF. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. J Am Coll Cardiol. 2007;49:1052-1058.
20. Di Carli MF, Dorbala S, Hachamovitch R. Integrated cardiac PET-CT for the diagnosis and management of CAD. J Nucl Cardiol. 2006;13: 139-144.
21. 13N-ammonia and validation with microspheres in a pig model. Circulation, 2009;119:2333-2342.
22. Yalamanchili P, Wexler E, Hayes M, Yu M, Bozek J, Kagan M, Radeke HS, Azure M, Purohit A, Casebier DS, Robinson SP. Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent. J Nucl Cardiol. 2007;14:782-788.
23. Yu M, Guaraldi MT, Mistry M, Kagan M, McDonald JL, Drew K, Radeke H, Azure M, Purohit A, Casebier DS, Robinson SP. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol. 2007;142:789-798.